Tirzepatide (Mounjaro / Zepbound): The Dual Agonist That's Rewriting Weight Loss Medicine

What Is Tirzepatide?

Tirzepatide is a synthetic peptide developed by Eli Lilly and Company. It is the first approved member of a new drug class called dual GIP/GLP-1 receptor agonists — sometimes referred to as "twincretins." Where prior-generation GLP-1 agonists like semaglutide target one gut hormone receptor, tirzepatide targets two simultaneously: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor.

It is administered as a once-weekly subcutaneous injection. Its structure is based on the native GIP sequence with modifications to improve GLP-1 receptor binding and dramatically extend its plasma half-life to approximately five days. This allows for once-weekly dosing with consistent receptor activation throughout the week.

The brand names: Mounjaro and Zepbound

Tirzepatide is marketed under two brand names that reflect its two FDA-approved indications:

• Mounjaro — FDA-approved in May 2022 for the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise
• Zepbound — FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition

The same active ingredient, the same doses, two different prescribing indications. Both require a prescription from a licensed healthcare provider.

The Dual GIP/GLP-1 Mechanism Explained

To understand why tirzepatide produces the metabolic effects it does, you have to understand the two hormones it mimics — and why their combination appears to be more than additive.

GLP-1: The appetite and insulin signal

Glucagon-like peptide-1 is released by L-cells in the small intestine within minutes of eating. Its key actions include:

• Glucose-dependent insulin secretion: Stimulates the pancreas to release insulin only when blood glucose is elevated, reducing hypoglycemia risk
• Glucagon suppression: Reduces glucagon (the counter-regulatory hormone that raises blood sugar)
• Gastric emptying delay: Slows how quickly food leaves the stomach, blunting post-meal glucose spikes and extending satiety
• Central appetite suppression: Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce appetite, food cravings, and "food noise"

These are the same mechanisms that make semaglutide effective. Tirzepatide binds and activates GLP-1 receptors in all the same locations — but with a binding profile that research suggests may produce somewhat different receptor dynamics than semaglutide.

GIP: The underestimated partner

Glucose-dependent insulinotropic polypeptide (GIP) was historically thought to be a minor insulin-secretion hormone — the less interesting half of the incretin duo. That assumption has been substantially revised by the data from tirzepatide trials.

GIP receptors are found in adipose (fat) tissue, the central nervous system, bone, and the pancreas. Research suggests that dual GIP/GLP-1 activation produces:

• Enhanced central appetite suppression: GIP receptors in the brain — particularly the ventromedial hypothalamus — appear to act synergistically with GLP-1 receptors to amplify satiety signals
• Improved energy expenditure: Some preclinical and human mechanistic data suggest GIP co-activation increases metabolic rate modestly beyond what GLP-1 agonism alone achieves
• Better tolerability (potentially): Paradoxically, GIP agonism may buffer some of the GI side effects associated with pure GLP-1 activation — though this remains an area of active research
• Adipose tissue remodeling: GIP receptors on fat cells may facilitate fat redistribution and storage changes independent of weight loss per se

Brain-centric effects: where the weight loss really happens

The most significant contributor to tirzepatide's weight loss effect isn't in the gut — it's in the central nervous system. PET imaging and mechanistic studies suggest that GLP-1 and GIP receptors in the hypothalamus and brainstem regulate the motivational and hedonic components of eating: not just hunger, but the desire for calorie-dense foods, the pleasure response to eating, and the persistent mental preoccupation with food. When both receptor pathways are activated simultaneously, the subjective suppression of food-seeking behavior appears to be more complete than with GLP-1 agonism alone.

FDA Approval: Mounjaro vs. Zepbound

Tirzepatide has two distinct FDA-approved products. Understanding the difference matters practically — for insurance coverage, prescribing criteria, and what your provider can document on a prescription.

Standard titration schedule

Regardless of brand, the prescribing guidance calls for slow, deliberate dose escalation:

1. Start at 2.5 mg/week for 4 weeks (this sub-therapeutic dose exists purely to build GI tolerance)
2. Increase to 5 mg/week for at least 4 weeks
3. Continue titrating in 2.5 mg increments every 4 weeks as tolerated, toward a target maintenance dose
4. Most clinical trial participants with obesity reached 10–15 mg/week as their maintenance dose

Rushing this titration schedule is the most common cause of severe GI side effects. The 4-week window at each dose level is clinically important — it allows GI tolerance to develop before escalation.

What the SURMOUNT Trials Actually Show

The SURMOUNT trial program is the clinical evidence base for tirzepatide in obesity. It comprises four major Phase 3 trials, with additional disease-specific studies ongoing. The results consistently exceeded the most optimistic pre-trial projections.

SURMOUNT-1: The flagship weight loss trial

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with weight-related conditions) but without type 2 diabetes. At 72 weeks:

The 5 mg and 10 mg doses produced mean losses of 16% and 19.5% respectively. Placebo participants lost 3.1%. No prior obesity medication had achieved these average results in a Phase 3 trial. For context, bariatric surgery (sleeve gastrectomy) typically produces 25–30% total body weight loss.

SURMOUNT-2: Patients with type 2 diabetes

SURMOUNT-2 examined weight loss in 938 adults with both obesity/overweight and type 2 diabetes — a population where weight loss is typically harder to achieve. Results at 72 weeks: mean body weight reduction of 15.7% (15 mg) and 13.9% (10 mg) versus 3.3% placebo. Glycemic improvements were also substantial: HbA1c dropped an average of 2.1 percentage points at the highest dose.

SURMOUNT-3: Weight loss maintenance after intensive behavioral intervention

Participants first completed a 12-week intensive lifestyle intervention (approximately 800 kcal/day) to achieve initial weight loss. They then were randomized to tirzepatide or placebo for an additional 72 weeks. The tirzepatide group continued losing an average of 18.4% additional body weight, while the placebo group regained weight. Total weight loss from baseline: approximately 26.2% for tirzepatide vs. 3.2% for placebo.

SURMOUNT-4: What happens when you stop?

Like semaglutide, tirzepatide's benefits are contingent on continued use. SURMOUNT-4 demonstrated that patients who completed 36 weeks of tirzepatide treatment and then were switched to placebo regained an average of 14 percentage points of their lost weight over the next 52 weeks — while those continuing tirzepatide maintained their weight loss. This confirms tirzepatide is a treatment, not a cure: it must be continued to maintain results.

SURPASS program: Diabetes efficacy trials

The SURPASS trials (a separate clinical program for type 2 diabetes management) included 8 studies enrolling more than 10,000 participants. SURPASS-2 — a head-to-head trial against semaglutide 1 mg/week in T2D patients — showed tirzepatide produced greater reductions in both HbA1c (by approximately 0.5 percentage points more) and body weight (by approximately 5.5 kg more) at the highest dose. These were the first head-to-head data between the two agents in a diabetes population.

Expanding indications: heart failure and sleep apnea

Post-approval trials have explored tirzepatide beyond diabetes and weight management:

• SUMMIT trial: In adults with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the risk of worsening heart failure events or cardiovascular death and improved physical limitation scores.
• SURMOUNT-OSA: In adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the apnea-hypopnea index (AHI) by 55–63% — a degree of improvement that made significant numbers of participants no longer require CPAP therapy.

Weight Loss & Broader Metabolic Benefits

The clinical picture with tirzepatide is broader than body weight reduction. Across the SURMOUNT and SURPASS programs, consistent metabolic improvements have been documented alongside weight loss.

Glycemic control and insulin sensitivity

Even in non-diabetic individuals, tirzepatide substantially improves insulin sensitivity and fasting glucose. SURMOUNT-1 participants without diabetes showed significant reductions in fasting glucose, insulin levels, and homeostatic model assessment of insulin resistance (HOMA-IR). These are improvements in metabolic health markers that have implications beyond the scale — they reflect a genuine shift in how the body processes glucose and energy.

Lipid improvements

Triglyceride levels typically fall substantially on tirzepatide — by 30–40% in some analyses — and HDL cholesterol tends to improve. LDL effects are more variable. These changes are consistent with the reduction in visceral fat, improvement in liver fat, and overall metabolic improvement associated with sustained weight loss.

Liver fat reduction (NASH/MAFLD)

Tirzepatide has shown striking reductions in liver fat content in both diabetic and non-diabetic populations. Phase 2 data from the SYNERGY-NASH trial demonstrated that tirzepatide resolved non-alcoholic steatohepatitis (NASH) — without worsening fibrosis — in a substantial proportion of participants with confirmed NASH. Phase 3 trials in liver disease are ongoing. This positions tirzepatide as a potentially significant intervention in metabolic-associated fatty liver disease (MAFLD).

Cardiovascular outcomes: the ongoing SURMOUNT-MMO trial

Semaglutide's cardiovascular benefit is well-established (SELECT trial, 2023: 20% reduction in MACE in high-risk patients without diabetes). Tirzepatide's large cardiovascular outcomes trial — SURMOUNT-MMO — is ongoing. The SUMMIT heart failure data provides some early cardiovascular evidence, but the primary MACE outcomes trial data for tirzepatide in a general at-risk population is not yet complete as of early 2026.

Side Effects & Safety Considerations

Tirzepatide is not well tolerated by everyone, and the side effect profile deserves honest discussion. Most adverse events are gastrointestinal, most are dose-dependent, and most improve with time — but the intensity during dose escalation can be significant for some people.

Gastrointestinal effects: by far the most common

In SURMOUNT-1, GI side effects were reported in the majority of tirzepatide participants. Frequency varied by dose and by week (highest during escalation):

• Nausea: ~30–44% (vs ~9% placebo)
• Diarrhea: ~17–30% (vs ~9% placebo)
• Vomiting: ~13–23% (vs ~2–3% placebo)
• Constipation: ~11–17% (vs ~5% placebo)
• Abdominal pain: ~8–11% (vs ~4% placebo)

GI side effects are most pronounced during the first 4–8 weeks at each new dose level, and the majority improve significantly with continued use. Practical mitigation: eat smaller, lower-fat meals; avoid eating too quickly; avoid lying down immediately after eating; stay well hydrated. Approximately 5–8% of trial participants discontinued due to GI intolerance.

Reduced caloric intake: nutritional considerations

One underappreciated consequence of tirzepatide's appetite suppression is the significant reduction in food intake — and with it, the risk of micronutrient insufficiency. If appetite is reduced by 30–40%, simply eating less of an existing diet may mean inadequate protein, vitamins, and minerals. A protein-first eating approach and consideration of micronutrient supplementation are commonly recommended.

Lean mass loss

Weight lost on tirzepatide is not purely fat. As with semaglutide and most other approaches to significant weight loss, a portion of the mass lost is skeletal muscle. Estimates from body composition analyses in SURMOUNT participants suggest lean mass may represent approximately 25–35% of total weight lost, with the proportion varying by protein intake, physical activity level, and rate of weight loss. Resistance exercise and protein-prioritized nutrition are the primary evidence-based strategies to mitigate this.

Serious but less common risks

Tirzepatide vs. Semaglutide: An Honest Comparison

Comparing tirzepatide and semaglutide is the question most people come to this article to answer. The trial data gives a reasonably clear answer on average weight loss. But averages aren't the whole story — individual response, tolerability, cardiovascular data, long-term track record, and cost all factor into which medication makes sense for a specific person.

What the SURMOUNT-5 head-to-head showed

The SURMOUNT-5 trial (published 2024) was the first prospective, randomized head-to-head comparison of tirzepatide 10 mg or 15 mg versus semaglutide 2.4 mg in adults with obesity (without diabetes). At 72 weeks, the tirzepatide group lost an average of approximately 20.2% of body weight versus 13.7% for semaglutide — a statistically significant difference representing about 47% greater relative weight loss. Nearly half (49%) of tirzepatide participants lost 25% or more of body weight, compared to 26% in the semaglutide group.

Where semaglutide still has an edge

The data consistently favors tirzepatide on weight loss magnitude. But a few areas remain where semaglutide has more supporting evidence:

• Cardiovascular outcomes: The SELECT trial is the largest completed CV outcomes trial in this class. Tirzepatide's equivalent study (SURMOUNT-MMO) is still enrolling as of early 2026.
• Long-term safety surveillance: Semaglutide has been on the market since 2017. More years of real-world pharmacovigilance data are available.
• Oral formulation: Oral semaglutide (Rybelsus) exists. No oral tirzepatide is currently approved (though trials are ongoing).
• Individual variability: Some patients are better responders to semaglutide. No reliable predictive biomarker exists yet — switching and titrating is still largely empirical.

For a complete primer on how semaglutide works, see our article: Semaglutide Explained: The Science Behind the Weight Loss Peptide →

Cost, Access & the Compounding Question

Cost is one of the most significant practical barriers to tirzepatide access — and the landscape has changed substantially since 2022, with compounding, shortage designations, and insurance dynamics all playing a role.

US list prices

Zepbound's list price is approximately $1,060 per month for most doses without insurance — somewhat lower than Wegovy. Eli Lilly has also offered a direct-to-consumer monthly supply program ("LillyDirect") at significant discounts for cash-pay patients without insurance coverage, at prices reported around $550–699/month for qualifying participants.

With commercial insurance coverage for a qualifying indication (obesity with comorbidity, or T2D), copays can vary from near-zero with manufacturer savings programs to several hundred dollars monthly. Medicare coverage has expanded following recent policy changes to allow GLP-1 agonists for weight management indications.

The compounding period and its conclusion

During 2022–2024, FDA drug shortage designations for both semaglutide and tirzepatide allowed licensed compounding pharmacies to produce and dispense compounded versions. Compounded tirzepatide became widely available at prices ranging from approximately $150–$400/month, dramatically expanding access during a period of supply constraints.

The FDA removed tirzepatide from its drug shortage list in late 2024, triggering enforcement actions against compounders continuing to produce copies. The regulatory window for large-scale compounded tirzepatide has effectively closed for most pharmacies. Limited custom compounding for individual patients with specific documented needs (e.g., specialized formulations for confirmed intolerances) may remain permissible in certain circumstances — but the mass-market compounded tirzepatide market is substantially restricted.

International access

Outside the United States, access and pricing vary substantially. Mounjaro is approved in the EU, UK, Canada, Japan, and several other markets for type 2 diabetes. Zepbound-equivalent approval for obesity has followed in many markets, though formulary inclusion and reimbursement differ widely. In some countries with universal healthcare (NHS, provincial plans), access criteria are restrictive and waiting lists are common.

Savings programs worth knowing

• Eli Lilly's Zepbound savings card: Commercially insured eligible patients may qualify for significant copay reductions
• LillyDirect: Eli Lilly's direct-to-patient telehealth/prescription program with discounted pricing for uninsured or underinsured patients
• Manufacturer patient assistance programs: Available for uninsured patients meeting income criteria

Who Is Tirzepatide Best Suited For?

Tirzepatide is a powerful pharmacological tool. But "more powerful" doesn't mean "right for everyone." Here's how to think about whether it might be appropriate for you — framed not as a checklist for self-diagnosis, but as a framework for a productive conversation with a healthcare provider.

Current FDA eligibility criteria

For Zepbound (weight management), FDA criteria are:

• BMI ≥30 (obesity), OR
• BMI ≥27 (overweight) with at least one weight-related condition: type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea
• Adults only (pediatric studies ongoing)
• Used as an adjunct to a reduced-calorie diet and increased physical activity

Who tends to be among the best candidates

Within the eligible population, certain profiles tend to show the strongest response and clearest benefit-to-risk ratio:

• People with significant metabolic comorbidities — prediabetes, insulin resistance, hypertriglyceridemia, fatty liver, HFpEF — where weight loss has clear systemic benefit beyond aesthetics
• People who have tried meaningful lifestyle intervention (dietary changes, exercise) and achieved limited sustained results
• People willing and able to commit to the slow titration schedule and accompanying lifestyle modifications
• People with access to prescriber oversight for monitoring and management of side effects and lab values

Situations that favor semaglutide instead

Tirzepatide isn't always the better choice even when both are eligible options:

• If cardiovascular outcome data is a priority consideration — semaglutide's SELECT trial data is more mature
• If you prefer a longer post-market safety track record
• If cost or insurance coverage is substantially better for semaglutide in your specific situation
• Prior tolerance: some patients simply tolerate one agent better than another for reasons that aren't fully predictable pre-trial

Absolute contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Pregnancy (must discontinue at least 2 months prior to planned conception)
• History of acute pancreatitis (relative contraindication — risk-benefit discussion required)
• Severe gastroparesis or other serious GI motility disorders

What "commitment" actually means

Tirzepatide is a long-term medication, not a short course. The evidence strongly suggests that stopping leads to weight regain for most people. Before starting, it's worth having an honest conversation with your provider about:

• What your long-term plan is — do you intend to take this indefinitely?
• What happens if supply, insurance, or financial circumstances change?
• How you plan to preserve lean mass (protein intake, resistance exercise) during active weight loss
• What lifestyle habits you're building during the treatment window to support long-term metabolic health

For context on how tirzepatide fits into the broader peptide landscape — including non-prescription peptides studied for very different purposes — see our Peptide Reference Database, or explore how the reconstitution math works for injectable peptides with our free peptide calculator.